Trending News

CAR-T cell therapy
#Bristol Myers Squibb #CAR-T #Cell therapy #Clinical trials #Novartis

Novartis and BMS pause CAR-T trials due to safety concerns

Novartis and Bristol Myers Squibb (BMS) have both paused clinical trials of CAR-T cell therapies for lupus and other autoimmune diseases due to concerning safety findings.  Novartis has placed holds on trials of rapcabtagene autoleucel (rap-cel), stopping screening, randomisation, and treatment administration in trials in lupus, myasthenia… Read More

#News #Trending News

handshake
#Autoimmune disease #Eli Lilly #Immunology #Mergers and acquisitions

Merida acquisition strengthens Lilly’s immunology capabilities

Eli Lilly has announced plans to acquire Merida Biosciences, a biotechnology company advancing a new class of precision therapeutics for serious autoimmune and allergic diseases.  Merida is developing biologics engineered to selectively degrade pathogenic autoantibodies, the disease-causing agents behind a range of immune-mediated conditions.   The precision degradation approach is intended… Read More

#Business & Investment #News #Trending News

Close up of vaccine syringe
#CEPI #Ebola virus #Immunology / Virology & Vaccines #Outbreak

CEPI backs Minapharm’s Bundibugyo ebolavirus vaccine candidate

African biopharmaceutical company Minapharm Group will receive up to $16.5 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of a Bundibugyo ebolavirus vaccine candidate.  The investment is part of efforts to develop vaccines to combat the fastest-growing and second-largest Ebola outbreak on… Read More

#News #Trending News

Colon cancer
#Colorectal cancer #Epigenetics #Juntendo University #Oncology

Study reveals how IL-26 reprogrammes colorectal cancer cells

Researchers have identified inflammatory cytokine interleukin-26 (IL-26) as a factor that acts on cancer cells and induces epigenetic reprogramming, promoting immune evasion.  While cancer cells acquire malignant traits through epigenetic remodelling, it remains unclear how immune-derived inflammatory factors regulate the epigenetics of colorectal cancer cells.  … Read More

#Cancer Research #News #Trending News

Patient receiving vaccine
#Immunology / Virology & Vaccines #National Institute for Health Research #Phase I trial #Stablepharma #Vaccines

Fridge-free vaccine effective at 30°C for at least two years

The world-first trial of a fridge-free tetanus-diphtheria vaccine has produced encouraging results that could improve access worldwide to crucial treatments.   Around half of vaccines are wasted globally each year, according to the World Health Organization, because of temperature changes during storage and transport.  Fridge-free vaccines… Read More

#News #Trending News

Ebola outbreak
#CEPI #Ebola virus #Immunology / Virology & Vaccines #Moderna #Outbreak

Phase I trial “a major step forward” against Ebola outbreak

Following Health Canada’s authorisation, the first participants have been vaccinated in Moderna’s Phase I clinical study evaluating mRNA-1469, an mRNA vaccine to prevent Bundibugyo ebolavirus (BDBV).  “Vaccinating the first participants with mRNA-1469 marks an important milestone in advancing a vaccine candidate against Bundibugyo ebolavirus, for which no… Read More

#Editor's Choice #News #Trending News

Eli Lilly Gateway Labs in South San Francisco, California.
#Eli Lilly #GLP-1 #Market reporting #Norstella

New index reveals Eli Lilly as the top ranked company

Norstella has announced the launch of the Pipeline-to-Patient Productivity Index (P3i), a new annual benchmark measuring R&D productivity, market access, and commercial return across the top 25 global biopharma companies.  The P3i is the first benchmark to follow drug performance across the entire development and commercialisation lifecycle. The index is… Read More

#Business & Investment #News #Trending News

#Department of Health and Social Care #Science #UK government #UK science #UK science minister

Chris McDonald appointed UK science minister

Chris McDonald has been appointed the UK’s new science minister following the resignation of Patrick Vallance. McDonald, who became a Minister of State at the newly formed Department for Business, Innovation, Science and Trade (Dbist) on 21 July, also took up a role at the Department of Health and Social… Read More

#News #Trending News

Retatrutide
#Eli Lilly #GLP-1 #Obesity #Phase III trial #Weight loss

Phase III trials confirm benefits of Lilly’s triple agonist retatrutide

Eli Lilly has announced positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase III trials evaluating retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist.   In both studies, retatrutide met the primary endpoint, delivering substantial weight loss in adults with obesity and some… Read More

#News #Trending News

International Space Station (ISS)
#Drug discovery #ETH Zurich #Switzerland

Swiss institutes pioneer microgravity drug discovery research

As the world celebrates International Moon Day (20 July), Switzerland is championing the opportunities space exploration opens for life sciences.  Leading international players including Starlab Space and Axiom Space have selected Switzerland as their European hub for the next generation of commercial orbital laboratories, supporting R&D in space.  “Swiss research… Read More

#Business & Investment #News #Trending News

Cancer cells
#Cancer Research UK #Clinical trials #Oncology #Peptides

Cancer Research UK leads global trial of rare cancer therapy 

Cancer Research UK is leading a group of partners launching a global Phase II trial into rare adrenal gland cancer.  Biotechnology company Cytovation and the Norwegian Cancer Society (NCS) have joined forces with Cancer Research UK for the trial of people with advanced adrenocortical carcinoma (ACC), a rare and… Read More

#News #Trending News

Claude AI app
#AI / data analytics / healthtech / informatics #Anthropic #Artificial intelligence (AI) #Drug discovery

Anthropic launches into drug discovery with Claude Science

Anthropic has launched Claude Science, an app that it says integrates the tools and packages that researchers most commonly use, produces auditable artifacts, and provides flexible access to computing resources.  At the launch event, the company also announced that it will be using the product to pursue some of its… Read More

#Business & Investment #Editor's Choice #News #Trending News

#Base editing #Beam Therapeutics #FDA #Gene editing #Gene therapy #Rare disease

FDA clears base editing therapy for phenylketonuria

The US Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for Beam Therapeutics’ BEAM-304 for the treatment of phenylketonuria (PKU).   PKU is a rare, inherited metabolic disorder that results in toxic accumulation of phenylalanine (Phe), leading to serious neurologic and neurocognitive impairments and requires strict,… Read More

#News #Regulatory #Trending News

GSK offices
#Biopharma #GSK #Non-small cell lung cancer (NSCLC)

GSK acquires Nuvalent and cancer therapy pipeline 

GSK has reached an agreement to acquire biopharmaceutical company Nuvalent for $10.6 billion.  The agreement includes GSK’s purchase of three therapies for lung cancer, including Zidesamtinib (NVL-250) and neladalkib (NVL-655). The candidates are late-stage, potential best-in-class, next-generation, highly selective ROS1 and ALK inhibitors for treatment of non-small cell lung cancer (NSCLC). … Read More

#Business & Investment #News #Trending News

#Collaboration #Innovent #Oncology #Pfizer

Pfizer and Innovent Biologics ink $10.5 billion oncology deal

Pfizer and Innovent Biologics have entered into a collaboration agreement for the research and development of 12 new early-stage cancer medicines, worth up to $10.5 billion.  The companies say the partnership includes licensing, co-development, and co-commercialisation opportunities across a portfolio of antibody-drug conjugates (ADCs) with differentiated payloads and multi-specific antibodies… Read More

#Business & Investment #News #Trending News

Vaccine discovery
#Ebola virus #Immunology / Virology & Vaccines #Outbreak #University of Oxford

UK group steps up Ebolavirus vaccine development in response to outbreak

In response to the current Bundibugyo Ebolavirus outbreak in the Democratic Republic of the Congo, the Oxford Vaccine Group (OVG) has reported that it is working urgently with the Clinical BioManufacturing Facility and the Serum Institute of India (SIIPL) to rapidly produce and scale doses of its ChAdOx-based monovalent… Read More

#News #Trending News